181 related articles for article (PubMed ID: 36715711)
1. Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia.
Inoue Y; Takekuma Y; Miyai T; Kashiwagi H; Sato Y; Sugawara M; Imai S
Eur J Clin Pharmacol; 2023 Mar; 79(3):415-425. PubMed ID: 36715711
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia.
Onita T; Ishihara N; Ikebuchi A; Yano T; Nishimura N; Tamaki H; Ikawa K; Morikawa N; Naora K
J Clin Pharm Ther; 2022 Dec; 47(12):2041-2048. PubMed ID: 35893441
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis.
Zhang D; Xu Y; Wang X; Hou L; Xing M; Xu S; Guo R; Luo Y
Eur J Clin Pharmacol; 2023 Oct; 79(10):1303-1314. PubMed ID: 37578552
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients.
Dai Y; Jiang S; Chen X; Han L; Zhang C; Yu X; Zhang X
J Clin Pharm Ther; 2021 Jun; 46(3):807-813. PubMed ID: 33555057
[TBL] [Abstract][Full Text] [Related]
5. Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study.
Thi Phuong Thao L; Duc Trung N; Thi My L; Minh Hong L; Viet Hoan B; Quang Hung V; Dang Hai P
J Infect Dev Ctries; 2024 Feb; 18(2):285-290. PubMed ID: 38484357
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia.
Hanai Y; Matsuo K; Ogawa M; Higashi A; Kimura I; Hirayama S; Kosugi T; Nishizawa K; Yoshio T
J Infect Chemother; 2016 Aug; 22(8):536-42. PubMed ID: 27321773
[TBL] [Abstract][Full Text] [Related]
7. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.
Ichie T; Suzuki D; Yasui K; Takahashi H; Matsuda M; Hayashi H; Sugiura Y; Sugiyama T
J Clin Pharm Ther; 2015 Jun; 40(3):279-84. PubMed ID: 25732525
[TBL] [Abstract][Full Text] [Related]
8. Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days.
Sato Y; Iguchi M; Kato Y; Morioka H; Hirabayashi A; Tetsuka N; Tomita Y; Kato D; Yamada K; Kimura H; Yagi T
Nagoya J Med Sci; 2020 Aug; 82(3):407-414. PubMed ID: 33132425
[TBL] [Abstract][Full Text] [Related]
9. A Regression Model to Predict Linezolid Induced Thrombocytopenia in Neonatal Sepsis Patients: A Ten-Year Retrospective Cohort Study.
Duan L; Zhou Q; Feng Z; Zhu C; Cai Y; Wang S; Zhu M; Li J; Yuan Y; Liu X; Sun J; Yang Z; Tang L
Front Pharmacol; 2022; 13():710099. PubMed ID: 35185555
[No Abstract] [Full Text] [Related]
10. Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: a matched case-control study.
Chen C; Li Y; Yu J; Qian S
Clin Transl Oncol; 2022 Mar; 24(3):540-545. PubMed ID: 34716540
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy.
Chen C; Guo DH; Cao X; Cai Y; Xu Y; Zhu M; Ma L
Curr Ther Res Clin Exp; 2012 Dec; 73(6):195-206. PubMed ID: 24653521
[TBL] [Abstract][Full Text] [Related]
12. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin.
Hiraki Y; Tsuji Y; Matsumoto K; Morita K; Kamimura H; Karube Y
Am J Med Sci; 2011 Dec; 342(6):456-60. PubMed ID: 21681075
[TBL] [Abstract][Full Text] [Related]
13. Linezolid-Induced Thrombocytopenia Is Caused by Suppression of Platelet Production via Phosphorylation of Myosin Light Chain 2.
Tajima M; Kato Y; Matsumoto J; Hirosawa I; Suzuki M; Takashio Y; Yamamoto M; Nishi Y; Yamada H
Biol Pharm Bull; 2016; 39(11):1846-1851. PubMed ID: 27803456
[TBL] [Abstract][Full Text] [Related]
14. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction.
Tsuji Y; Hiraki Y; Matsumoto K; Mizoguchi A; Kobayashi T; Sadoh S; Morita K; Kamimura H; Karube Y
J Infect Chemother; 2011 Feb; 17(1):70-5. PubMed ID: 20582446
[TBL] [Abstract][Full Text] [Related]
15. [Risk factors for development of hematotoxicity in elderly patients treated with Linezolid].
Bo SY; Su AM; Yang F; Yang L
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jun; 45(6):533-538. PubMed ID: 35658376
[No Abstract] [Full Text] [Related]
16. Reversible recurrent profound thrombocytopenia due to linezolid in a patient with multi-drug resistant tuberculosis: A case report.
Wang MG; Wang D; He JQ
Medicine (Baltimore); 2018 Aug; 97(34):e11997. PubMed ID: 30142839
[TBL] [Abstract][Full Text] [Related]
17. Thrombocytopenia in Patients Receiving Prolonged Linezolid May be Caused by Oxidative Stress.
Wang TL; Guo DH; Bai Y; Wen K; Han WY; Wang R
Clin Drug Investig; 2016 Jan; 36(1):67-75. PubMed ID: 26507619
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for linezolid-induced thrombocytopenia in adult inpatients.
Han X; Wang J; Zan X; Peng L; Nie X
Int J Clin Pharm; 2022 Apr; 44(2):330-338. PubMed ID: 34731363
[TBL] [Abstract][Full Text] [Related]
19. A retrospective test for a possible relationship between linezolid-induced thrombocytopenia and hyponatraemia.
Tanaka R; Suzuki Y; Morinaga Y; Iwao M; Takumi Y; Hashinaga K; Tatsuta R; Hiramatsu K; Kadota JI; Itoh H
J Clin Pharm Ther; 2021 Apr; 46(2):343-351. PubMed ID: 33016566
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study.
Tsutsumi T; Imai S; Kashiwagi H; Sato Y; Sugawara M; Takekuma Y
Eur J Clin Pharmacol; 2022 Feb; 78(2):279-286. PubMed ID: 34581841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
